CLAIMS:

1. A pharmaceutical composition for use in treating of Alzheimer's disease comprising an anti-Aβ protofibril antibody and N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide or a pharmaceutically acceptable salt thereof,

wherein the antibody comprises (a) a heavy chain variable domain comprising an amino acid sequence of SEQ ID NO:1 and (b) a light chain variable domain comprising an amino acid sequence of SEQ ID NO:2.

2. The pharmaceutical composition of claim 1, wherein (a) the heavy chain constant region further comprises an amino acid sequence of SEQ ID NO:3 and (b) the light chain constant region further comprises an amino acid sequence of SEQ ID NO:4.

3. The pharmaceutical composition of claim 1, wherein N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide is in the form of a free base.

4. Use of anti-Aβ protofibril antibody and N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide and/or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating Alzheimer's disease,

wherein the antibody comprises (a) a heavy chain variable domain comprising an amino acid sequence of SEQ ID NO:1 and (b) a light chain variable domain comprising an amino acid sequence of SEQ ID NO:2; and

wherein the medicament is adapted for administration of the antibody at a dose ranging from 2.5 mg/kg to 10 mg/kg, and

wherein the medicament is adapted for administration of N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide and/or a pharmaceutically acceptable salt thereof at a dose ranging from 5 mg/day to 50 mg/day.

5. The use of claim 4, wherein the medicament is adapted for administration of

N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide and/or a pharmaceutically acceptable salt thereof at a dose ranging from 15 mg/day to 50 mg/day.

6. The use of claim 4, wherein the medicament is adapted for administration of N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide and/or a pharmaceutically acceptable salt thereof at a dose of 50 mg/day.

7. The use of any one of claims 4-6, wherein the medicament is adapted for administration of the antibody at a dose ranging from 5 mg/kg to 10 mg/kg.

8. The use of any one of claims 4-6, wherein the medicament is adapted for administration of the antibody at a dose of 10 mg/kg.

9. The use of any one of claims 4-8, wherein the medicament is adapted for administration of the antibody every 2 weeks.

10. The use of any one of claims 4-8, wherein the medicament is adapted for administration of the antibody every month.

11. The use of any one of claims 4-10, wherein (a) the heavy chain constant region further comprises an amino acid sequence of SEQ ID NO:3 and (b) the light chain constant region further comprises an amino acid sequence of SEQ ID NO:4.

12. The use of any one of claims 4-11, wherein N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide is in the form of a free base.